DE2748520A1 - Hepatitis b-dane-teilchen - Google Patents
Hepatitis b-dane-teilchenInfo
- Publication number
- DE2748520A1 DE2748520A1 DE19772748520 DE2748520A DE2748520A1 DE 2748520 A1 DE2748520 A1 DE 2748520A1 DE 19772748520 DE19772748520 DE 19772748520 DE 2748520 A DE2748520 A DE 2748520A DE 2748520 A1 DE2748520 A1 DE 2748520A1
- Authority
- DE
- Germany
- Prior art keywords
- density gradient
- dane particles
- gradient
- sodium bromide
- dane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims description 46
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- 239000013060 biological fluid Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 8
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 229940037003 alum Drugs 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000000677 immunologic agent Substances 0.000 claims description 4
- 229940124541 immunological agent Drugs 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- 229940124272 protein stabilizer Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims 5
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229910052792 caesium Inorganic materials 0.000 claims 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 2
- 229940111695 potassium tartrate Drugs 0.000 description 2
- 239000001472 potassium tartrate Substances 0.000 description 2
- 235000011005 potassium tartrates Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D43/00—Separating particles from liquids, or liquids from solids, otherwise than by sedimentation or filtration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73786276A | 1976-11-02 | 1976-11-02 | |
| US05/784,191 US4129646A (en) | 1976-11-02 | 1977-04-04 | Isolating hepatitis B Dane particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2748520A1 true DE2748520A1 (de) | 1978-05-03 |
| DE2748520C2 DE2748520C2 (enrdf_load_stackoverflow) | 1987-07-30 |
Family
ID=27113269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19772748520 Granted DE2748520A1 (de) | 1976-11-02 | 1977-10-28 | Hepatitis b-dane-teilchen |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5379011A (enrdf_load_stackoverflow) |
| DE (1) | DE2748520A1 (enrdf_load_stackoverflow) |
| FR (3) | FR2394297A1 (enrdf_load_stackoverflow) |
| GB (2) | GB1554400A (enrdf_load_stackoverflow) |
| NL (1) | NL7711378A (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2816864A1 (de) * | 1977-04-20 | 1978-10-26 | Merck & Co Inc | Hepatitis b-kern-antigen |
| DE3049690A1 (de) * | 1979-07-05 | 1982-02-18 | Alpha Therapeutic Corp | Process for producing hepatitis b vaccine |
| DE3150935A1 (de) * | 1981-12-23 | 1983-06-30 | Uwe Dr.med. 3400 Göttingen Böttcher | Verfahren zur herstellung eines hepatitis-b impfstoffes |
| EP0114291A3 (de) * | 1983-01-24 | 1985-12-04 | Bodo Dr. Plewinsky | Mittel zur Trennung gelöster und/oder ungelöster Stoffe aufgrund unterschiedlicher Auftriebsdichten bzw. Dichten vermittels der Lösungen echter Metawolframate |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK366778A (da) * | 1978-08-18 | 1980-02-19 | Foss Electric As | Fremgangsmaade til taelling af bakterier |
| FR2561256B1 (fr) * | 1984-03-16 | 1987-01-02 | Pasteur Institut | Procede de purification de particules biologiques de type antigene hbs, par ultracentrifugation de flottation sur gradient de densite |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1356413A (en) * | 1971-09-09 | 1974-06-12 | Pfizer Ltd | Method of obtaining purified australia antigen from blood serum |
| US4029764A (en) * | 1974-12-09 | 1977-06-14 | Merck & Co., Inc. | Hepatitis A antigen |
| US4024243A (en) * | 1975-06-16 | 1977-05-17 | Merck & Co., Inc. | Process for isolating hepatitis B antigen |
| FR2412315A1 (fr) * | 1977-02-23 | 1979-07-20 | Merck & Co Inc | Procede de preparation d'un antigene de l'hepatite b et l'antigene obtenu |
| GB1554811A (en) * | 1977-02-23 | 1979-10-31 | Merck & Co Inc | Purifying hepatitis b surface antigen |
-
1977
- 1977-10-17 NL NL7711378A patent/NL7711378A/xx not_active Application Discontinuation
- 1977-10-28 DE DE19772748520 patent/DE2748520A1/de active Granted
- 1977-10-28 FR FR7732653A patent/FR2394297A1/fr active Granted
- 1977-10-31 GB GB859078A patent/GB1554400A/en not_active Expired
- 1977-10-31 GB GB4523877A patent/GB1554399A/en not_active Expired
- 1977-11-02 JP JP13093077A patent/JPS5379011A/ja active Granted
-
1979
- 1979-04-25 FR FR7910456A patent/FR2422406A1/fr active Granted
- 1979-04-25 FR FR7910455A patent/FR2422399A1/fr active Granted
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2816864A1 (de) * | 1977-04-20 | 1978-10-26 | Merck & Co Inc | Hepatitis b-kern-antigen |
| DE3049690A1 (de) * | 1979-07-05 | 1982-02-18 | Alpha Therapeutic Corp | Process for producing hepatitis b vaccine |
| DE3150935A1 (de) * | 1981-12-23 | 1983-06-30 | Uwe Dr.med. 3400 Göttingen Böttcher | Verfahren zur herstellung eines hepatitis-b impfstoffes |
| EP0114291A3 (de) * | 1983-01-24 | 1985-12-04 | Bodo Dr. Plewinsky | Mittel zur Trennung gelöster und/oder ungelöster Stoffe aufgrund unterschiedlicher Auftriebsdichten bzw. Dichten vermittels der Lösungen echter Metawolframate |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS635381B2 (enrdf_load_stackoverflow) | 1988-02-03 |
| FR2394297A1 (fr) | 1979-01-12 |
| FR2422406B1 (enrdf_load_stackoverflow) | 1982-11-19 |
| FR2422399A1 (fr) | 1979-11-09 |
| JPS5379011A (en) | 1978-07-13 |
| GB1554400A (en) | 1979-10-17 |
| DE2748520C2 (enrdf_load_stackoverflow) | 1987-07-30 |
| FR2422406A1 (fr) | 1979-11-09 |
| FR2394297B1 (enrdf_load_stackoverflow) | 1982-11-19 |
| FR2422399B1 (enrdf_load_stackoverflow) | 1982-11-19 |
| GB1554399A (en) | 1979-10-17 |
| NL7711378A (nl) | 1978-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2707881C2 (de) | Verfahren zum Nachweis von rheumatoiden Faktoren | |
| DE2801123A1 (de) | Verfahren zur herstellung eines intravenoes applizierbaren serumeiweiss- praeparates | |
| DE3786832T2 (de) | Verfahren zur Herstellung von Immunoglobulinzubereitungen für intravenöse Injektion. | |
| DE3346336A1 (de) | Verfahren zur herstellung von erythropoetin | |
| DE2624815B2 (de) | Herstellung einer injizierbaren, stromafreien und von Plasmaproteinen freien Hämoglobinlösung | |
| DE2500076A1 (de) | Verfahren zur erhoehung der intravenoesvertraeglichkeit von aus blut oder blutprodukten ausgefaellten gammaglobulinen | |
| DE3105555C2 (enrdf_load_stackoverflow) | ||
| DE2403994A1 (de) | Herstellung von antisera | |
| DE2748520A1 (de) | Hepatitis b-dane-teilchen | |
| DE2658170A1 (de) | Arzneimittel zur behandlung der durch den hepatitisvirus b ausgeloesten akuten oder chronischen infektionen | |
| DE2551576C3 (de) | Träger für immunochemische Messungen | |
| CH630643A5 (en) | Process for concentrating a placenta-specific glycoprotein. | |
| DE2707913C2 (de) | Verfahren zum Nachweis von rheumatoiden Faktoren | |
| DE2025718C3 (de) | Verfahren zum Stabilisieren von lyophillsierten Erythrozyten | |
| DE2703620C2 (de) | Verfahren zur Herstellung eines Konzentrats des Antihämophiliefaktors | |
| DE2515666C3 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE3028977A1 (de) | Verfahren zur ausstellung von antikoerperserum mit erhoehter agglutinationsaktivitaet | |
| DE2440926C3 (de) | Injizierbarer inaktivierter Impfstoff gegen Hepatitis B und Verfahren zu seiner Herstellung | |
| DE2235600B2 (de) | Verfahren zur Reinigung von T -Globulin | |
| DE2243237A1 (de) | Nachweis der immunreaktion gegenueber krebs | |
| DE2062558A1 (de) | Mittel zur Diagnose von primärem Leberkrebs und Verfahren zur Her stellung desselben | |
| DE1598859C (de) | Verfahren zur Herstellung von Reagen zien für immunochemische Bestimmungen | |
| DE2353035A1 (de) | Verfahren zur stabilisierung menschlicher oder tierischer koerperfluessigkeiten oder pflanzlicher extrakte | |
| DE2533183C3 (de) | Verfahren zum Herstellen gereinigter Immunglobuline | |
| DE2602892A1 (de) | Konzentriertes hepatitis-b-oberflaechenantigen enthaltende masse und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |